Innova Captab (INNOVACAP) Stock Overview
An integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
No risks detected for INNOVACAP from our risk checks.
INNOVACAP Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Innova Captab Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹941.35 |
| 52 Week High | ₹980.00 |
| 52 Week Low | ₹622.00 |
| Beta | 0.011 |
| 1 Month Change | 11.24% |
| 3 Month Change | 40.22% |
| 1 Year Change | 9.51% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 73.87% |
Recent News & Updates
Narrative Update • Jun 26
INNOVACAP: Higher Fair Value And Governance Moves Will Support Bullish Re Rating
Analysts have revised their price target for Innova Captab to ₹1,078.50 from ₹891.50, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key inputs to the new valuation view. What’s in the News for Innova Captab The board has scheduled a meeting on May 25, 2026, to consider the reappointment of M/s.Analysis Article • May 12
Innova Captab Limited (NSE:INNOVACAP) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, Innova Captab Limited ( NSE:INNOVACAP ) recently reported its yearly numbers. It was a workmanlike...Analysis Article • May 09
If EPS Growth Is Important To You, Innova Captab (NSE:INNOVACAP) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Recent updates
Narrative Update • Jun 26
INNOVACAP: Higher Fair Value And Governance Moves Will Support Bullish Re Rating
Analysts have revised their price target for Innova Captab to ₹1,078.50 from ₹891.50, citing updated assumptions around the discount rate, revenue growth, profit margin, and future P/E as key inputs to the new valuation view. What’s in the News for Innova Captab The board has scheduled a meeting on May 25, 2026, to consider the reappointment of M/s.Analysis Article • May 12
Innova Captab Limited (NSE:INNOVACAP) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, Innova Captab Limited ( NSE:INNOVACAP ) recently reported its yearly numbers. It was a workmanlike...Analysis Article • May 09
If EPS Growth Is Important To You, Innova Captab (NSE:INNOVACAP) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Narrative Update • Apr 25
INNOVACAP: Stable Fair Value Assumptions Will Support Bullish Price Re Rating
Analysts have kept their fair value estimate for Innova Captab steady at ₹891.50, with only marginal tweaks to assumptions on discount rate, revenue growth, profit margin and future P/E that fine tune rather than change their overall view. Valuation Changes Fair Value: Kept unchanged at ₹891.50, indicating no shift in the central valuation outcome.Narrative Update • Apr 10
INNOVACAP: Upcoming Interim Dividend Review Will Support Bullish Price Re Rating
Analysts have kept their fair value estimate for Innova Captab steady at ₹891.50, citing essentially unchanged assumptions for discount rate, revenue growth, profit margin and future P/E that together support maintaining the existing price target. What's in the News Board meeting scheduled for Jan 23, 2026, at 12:00 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Narrative Update • Mar 27
INNOVACAP: Interim Dividend Decision Will Shape Bullish Return Potential
Analysts have kept the fair value estimate for Innova Captab steady at ₹891.5, with only minimal technical adjustments to inputs such as discount rate, revenue growth, profit margin and forward P/E. This reflects a largely unchanged view on the stock’s valuation drivers.Narrative Update • Mar 12
INNOVACAP: Interim Dividend Decision Will Support Bullish Share Outlook
Analysts are keeping their price target for Innova Captab steady at ₹891.5, citing largely unchanged assumptions around revenue growth, profit margins, discount rate and future P/E. What's in the News A board meeting is scheduled on Jan 23, 2026 at 12:00 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Narrative Update • Feb 26
INNOVACAP: Interim Dividend Review Will Support Bullish Outlook On Shares
Analysts have kept their price target for Innova Captab steady at ₹891.5, citing only minor technical adjustments to inputs such as discount rate, revenue growth, profit margin and future P/E that do not materially change their overall view. What's in the News Board meeting scheduled for Jan 23, 2026, at 12:00 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).Narrative Update • Feb 11
INNOVACAP: Upcoming Interim Dividend Decision Will Support Future Upside
Analysts now place their fair value estimate for Innova Captab at ₹891.5, up from ₹808.5. They cite updated assumptions around revenue growth, profit margins, discount rate and future P/E as key drivers of the change. What's in the News Board meeting scheduled on Jan 23, 2026 at 12:00 Indian Standard Time to review unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Narrative Update • Jan 27
INNOVACAP: Steadier Margins And Upcoming Dividends Will Support Future Upside
Analysts have slightly reduced their price expectations for Innova Captab, reflecting a modestly lower revenue growth outlook of 20.24% and a more conservative future P/E of 22.23x, while still anticipating some efficiency gains in profit margins at 11.70%. What's in the News Board meeting scheduled on Jan 23, 2026, at 12:00 Indian Standard Time to review and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Narrative Update • Jan 12
INNOVACAP: Stable Profitability Assumptions Will Support Future Upside Potential
Analysts have maintained their fair value estimate for Innova Captab at ₹808.50, with modest tweaks to the discount rate and future P/E assumptions guiding this unchanged price target. What's in the News A board meeting is scheduled for November 7, 2025, to consider, approve, and take on record the unaudited financial results for the quarter and half year ended September 30, 2025 (company filing).Narrative Update • Dec 15
INNOVACAP: Stable Margins And Growth Outlook Will Drive Future Upside Potential
Analysts have maintained their price target for Innova Captab at ₹808.5 per share, noting that only minor adjustments to the discount rate and long term valuation assumptions were needed, based on stable growth and margin expectations. What's in the News A board meeting is scheduled for November 7, 2025, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 (company board filing).Narrative Update • Nov 28
INNOVACAP: Improved Revenue Outlook Will Drive Bullish Momentum Ahead
Analysts have maintained their fair value price target for Innova Captab at ₹808.5. They cited minor adjustments in key financial assumptions, including the discount rate, revenue growth, and profit margin, to reflect updated expectations for the company's future performance. What's in the News Innova Captab Limited has scheduled a Board Meeting on November 7, 2025.Narrative Update • Nov 13
INNOVACAP: Revised Financial Outlook Will Reflect Adjusted Revenue and Discount Rate
Narrative Update on Innova Captab Analyst Price Target Analysts have lowered their price target for Innova Captab from ₹1,076 to ₹808.5. The revised outlook is attributed to adjustments to revenue growth projections and a higher discount rate. What's in the News A board meeting is scheduled for November 7, 2025, to consider and approve the unaudited financial results for the quarter and half year ended September 30, 2025 (Key Developments).Analysis Article • Nov 13
Analysts Just Slashed Their Innova Captab Limited (NSE:INNOVACAP) EPS Numbers
Market forces rained on the parade of Innova Captab Limited ( NSE:INNOVACAP ) shareholders today, when the analysts...New Narrative • Sep 06
New Jammu Facility Will Capture Global Healthcare Demand
Key Takeaways New state-of-the-art facility and expansion into branded generics and CDMO deepen client relationships and position the company for sustainable global revenue growth. Backward integration, cost-plus pricing, and R&D into specialized products are expected to drive margin improvement and long-term earnings stability.Analysis Article • Jun 20
A Look At The Intrinsic Value Of Innova Captab Limited (NSE:INNOVACAP)
Key Insights The projected fair value for Innova Captab is ₹745 based on 2 Stage Free Cash Flow to Equity Current share...Analysis Article • May 26
Additional Considerations Required While Assessing Innova Captab's (NSE:INNOVACAP) Strong Earnings
Despite announcing strong earnings, Innova Captab Limited's ( NSE:INNOVACAP ) stock was sluggish. We did some digging...Analysis Article • May 23
Innova Captab Limited (NSE:INNOVACAP) Just Released Its Full-Year Earnings: Here's What Analysts Think
Innova Captab Limited ( NSE:INNOVACAP ) shareholders are probably feeling a little disappointed, since its shares fell...Analysis Article • Mar 12
Innova Captab Limited's (NSE:INNOVACAP) Intrinsic Value Is Potentially 26% Below Its Share Price
Key Insights Innova Captab's estimated fair value is ₹588 based on 2 Stage Free Cash Flow to Equity Innova Captab's...Analysis Article • Feb 19
Innova Captab Limited's (NSE:INNOVACAP) 25% Share Price Plunge Could Signal Some Risk
Innova Captab Limited ( NSE:INNOVACAP ) shareholders won't be pleased to see that the share price has had a very rough...Analysis Article • Jan 29
Here's Why Innova Captab (NSE:INNOVACAP) Can Manage Its Debt Responsibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysis Article • Aug 01
Even With A 27% Surge, Cautious Investors Are Not Rewarding Innova Captab Limited's (NSE:INNOVACAP) Performance Completely
Despite an already strong run, Innova Captab Limited ( NSE:INNOVACAP ) shares have been powering on, with a gain of 27...Analysis Article • Jul 19
Innova Captab (NSE:INNOVACAP) Has A Pretty Healthy Balance Sheet
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Analysis Article • Jun 06
We Think That There Are Issues Underlying Innova Captab's (NSE:INNOVACAP) Earnings
Despite posting some strong earnings, the market for Innova Captab Limited's ( NSE:INNOVACAP ) stock hasn't moved much...Analysis Article • May 21
What Innova Captab Limited's (NSE:INNOVACAP) P/E Is Not Telling You
Innova Captab Limited's ( NSE:INNOVACAP ) price-to-earnings (or "P/E") ratio of 35.8x might make it look like a sell...Shareholder Returns
| INNOVACAP | IN Life Sciences | IN Market | |
|---|---|---|---|
| 7D | -0.9% | -0.9% | -0.5% |
| 1Y | 9.5% | -1.8% | -2.3% |
Return vs Industry: INNOVACAP exceeded the Indian Life Sciences industry which returned -1.8% over the past year.
Return vs Market: INNOVACAP exceeded the Indian Market which returned -2.3% over the past year.
Price Volatility
| INNOVACAP volatility | |
|---|---|
| INNOVACAP Average Weekly Movement | 5.3% |
| Life Sciences Industry Average Movement | 5.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 9.9% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: INNOVACAP has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: INNOVACAP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Vinay Lohariwala | innovacaptab.com |
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals.
Innova Captab Limited Fundamentals Summary
| INNOVACAP fundamental statistics | |
|---|---|
| Market cap | ₹53.87b |
| Earnings (TTM) | ₹1.41b |
| Revenue (TTM) | ₹16.30b |
38.2x
P/E Ratio3.3x
P/S RatioIs INNOVACAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INNOVACAP income statement (TTM) | |
|---|---|
| Revenue | ₹16.30b |
| Cost of Revenue | ₹10.66b |
| Gross Profit | ₹5.64b |
| Other Expenses | ₹4.23b |
| Earnings | ₹1.41b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 24.63 |
| Gross Margin | 34.60% |
| Net Profit Margin | 8.65% |
| Debt/Equity Ratio | 31.4% |
How did INNOVACAP perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield12%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/27 04:05 |
| End of Day Share Price | 2026/06/25 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innova Captab Limited is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Abdulkader Puranwala | ICICI Securities Ltd. |
| Amey Chalke | JM Financial Institutional Securities Limited |